CG Oncology (CGON) Cash & Equivalents (2023 - 2026)

CG Oncology's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $33.7 million for Q1 2026.

• Quarterly Cash & Equivalents fell 18.74% year-over-year to $33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.7 million (down 18.74% YoY) and the FY2025 annual result came in at $32.5 million, down 87.36% from the prior year.
• Cash & Equivalents was $33.7 million for Q1 2026 at CG Oncology, up from $32.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $257.1 million in Q4 2024 and bottomed at $8.3 million in Q4 2023.
• A 4-year average of $57.9 million and a median of $37.6 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 3009.94% — and 2025, when it plunged 87.36%.
• CG Oncology's Cash & Equivalents stood at $8.3 million in 2023, then jumped by 3009.94% to $257.1 million in 2024, then plunged by 87.36% to $32.5 million in 2025, then rose by 3.72% to $33.7 million in 2026.
• Business Quant data shows CGON's Cash & Equivalents at $33.7 million in Q1 2026, $32.5 million in Q4 2025, and $45.1 million in Q3 2025.